Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current concepts in coronary thrombolysis

G Grignani1, M Zucchella, A Brocchieri

  • 1Dipartimento di Medicina Interna e Terapia Medica, Università di Pavia, IRCCS Policlinico San Matteo, Italy.

Haematologica
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.

ESMO open·2025
Same author

TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group.

ESMO open·2024
Same author

Frequency-Dependent Squeezed Vacuum Source for the Advanced Virgo Gravitational-Wave Detector.

Physical review letters·2023
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

Thrombolytic therapy is standard for acute myocardial infarction, with both fibrin-specific and non-specific drugs offering benefits and risks. Improving patient access to these treatments remains a priority for better outcomes.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Thrombolytic therapy is a cornerstone in managing acute myocardial infarction.
  • Fibrinolytic drugs are classified as non-fibrin specific (e.g., streptokinase) or fibrin-specific (e.g., t-PA).
  • Both drug classes impact hemostatic balance, exhibiting antithrombotic and prothrombotic properties.

Purpose of the Study:

  • To review the current landscape of thrombolytic therapy in acute myocardial infarction.
  • To discuss the mechanisms and effects of different thrombolytic agents on hemostasis.
  • To explore emerging strategies for enhancing thrombolytic treatment efficacy.

Main Methods:

  • Review of existing literature on thrombolytic agents and their clinical application in myocardial infarction.

Related Experiment Videos

  • Analysis of the hemostatic effects of fibrin-specific and non-fibrin-specific thrombolytics.
  • Discussion of novel therapeutic strategies and future research directions.

    • Main Results:

    • Non-fibrin-specific thrombolytics induce systemic fibrinolysis, while fibrin-specific agents target fibrin-bound plasminogen.
    • Thrombolytics possess dual hemostatic effects, potentially contributing to treatment failure or reocclusion.
    • Investigational strategies include combined agent administration, targeted delivery, and adjunctive therapies.

    Conclusions:

    • Despite excellent efficacy, increasing patient access to thrombolytic therapy is paramount.
    • Understanding the hemostatic effects of thrombolytics is crucial for optimizing treatment.
    • Ongoing research aims to further refine thrombolytic strategies for acute myocardial infarction.